Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
99.37(c) 98.68(c) 98.22(c) 100.55(c) 101.91(c) Last
1 320 517 3 190 272 2 432 560 1 659 512 3 134 069 Volume
+0.63% -0.69% -0.47% +2.37% +1.35% Change
More quotes
Financials (USD)
Sales 2020 2 449 M - -
Net income 2020 -334 M - -
Net cash position 2020 1 862 M - -
P/E ratio 2020 -66,4x
Yield 2020 -
Sales 2021 2 837 M - -
Net income 2021 670 M - -
Net cash position 2021 2 514 M - -
P/E ratio 2021 34,1x
Yield 2021 -
Capitalization 22 153 M 22 153 M -
EV / Sales 2020 8,29x
EV / Sales 2021 6,92x
Nbr of Employees 1 456
Free-Float 98,7%
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and cooperation agreements (3.6%).  
Sector
Biotechnology & Medical Research
Calendar
06/09 | 08:00amPresentation
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
05/29INCYTE : Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponat..
BU
05/28INCYTE : Pemazyre Available Exclusively at Biologics by McKesson
AQ
05/27INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
AQ
05/21INCYTE : MorphoSys and Incyte Announce the Validation of the European Marketing ..
AQ
05/21INCYTE : to Present at Upcoming Investor Conference
BU
05/20INCYTE : and MorphoSys Announce the Validation of the European Marketing Authori..
BU
05/14INCYTE CORP : Change in Directors or Principal Officers (form 8-K)
AQ
05/14INCYTE : Data from Incyte's Oncology Portfolio Accepted for Presentation at the ..
BU
05/07INCYTE : Novartis announces FDA approval of MET inhibitor Tabrecta for metastati..
AQ
05/06FDA Approves Novartis' Tabrecta for Metastatic Non-Small Cell Lung Cancer
DJ
05/06INCYTE : Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatmen..
BU
05/05INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/05INCYTE : 1Q Earnings Snapshot
AQ
05/05INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
05/05INCYTE : Reports 2020 First Quarter Financial Results and Provides Updates on Ke..
BU
More news
News in other languages on INCYTE CORPORATION
05/30INCYTE : Vorstellung der Zwischenergebnisse der offenen Phase-II-Studie OPTIC zu..
05/30INCYTE : Présentation des données intermédiaires de l'étude ouverte OPTIC de Pha..
05/29INCYTE : Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponat..
05/28INCYTE : Pemazyre Available Exclusively at Biologics by McKesson
05/27INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
More news
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 100,70 $
Last Close Price 101,91 $
Spread / Highest target 18,7%
Spread / Average Target -1,19%
Spread / Lowest Target -22,5%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION16.71%22 153
LONZA GROUP33.49%36 433
IQVIA HOLDINGS INC.-3.23%28 553
SEATTLE GENETICS, INC.37.59%27 213
MODERNA, INC.214.42%23 913
CELLTRION, INC.17.96%23 085